Sebastian Kreuz – Startup Investor Profile

Sebastian Kreuz is an investment manager at Boehringer Ingelheim Venture Fund focusing on strategic opportunities in the infectious diseases space. His geographical preference is to invest worldwide in innovative early-stage therapeutics and digital health companies. He has been involved in previous investments such as Centauri Therapeutics and Quantro Therapeutics. Sebastian’s track record includes roles in research and venture capital law. The investment check size for companies like QUANTRO Therapeutics is significant. His partnership and collaboration styles involve a focus on groundbreaking therapeutic approaches and technologies.

Location:

Country: Germany

Investment Regions: EU, MENA

Investment Stages: pre-seed, seed

Website: https://www.boehringer-ingelheim-venture.com/team.php

AI Reasoning: Search found a press release showing Dr Sebastian Kreuz participated as Investment Director in Centauri Therapeutics’ Series A announced 16 February 2022. Also Boehringer Ingelheim Venture Fund lists Quantro and Centauri in its portfolio; Quantro involvement is seed stage earlier. No evidence of investments in the last 12 months or within the 6-12 month window; the latest confirmed investment date is 16 Feb 2022, which is more than 12 months prior, however additional portfolio pages show activity but no later dates. Given the last known transaction is Feb 2022 (over 3 years ago), classification corresponds to low-active.

Low Activity – Only known angel investments more than 12 months ago.

Active – Known angel investments between the last 12 and 6 months.

Very Active – Known angel investments in the last 6 months.